Literature DB >> 18528824

Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?

Maria J Garcia-Rodriguez1, Miguel A Canales, Dolores Hernandez-Maraver, Fernando Hernandez-Navarro.   

Abstract

Reactivation of hepatitis B infection is an increasing problem for patients with lymphoma, even in resolved infections, who were treated with rituximab-based regimens. Our cases point out the need of prolonged prophylaxis in HBsAg-negative patients due to the high risk of developing fatal reactivation. Copyright 2008 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18528824     DOI： 10.1002/ajh.21214

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  20 in total

Review 1.  Does rituximab increase the incidence of infectious complications? A narrative review.

Authors:  Theodoros Kelesidis; George Daikos; Dimitrios Boumpas; Sotirios Tsiodras
Journal:  Int J Infect Dis       Date:  2010-11-11       Impact factor: 3.623

Review 2.  Living in the liver: hepatic infections.

Authors:  Ulrike Protzer; Mala K Maini; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2012-02-24       Impact factor: 53.106

Review 3.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

4.  The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.

Authors:  Xiao-Qin Chen; Jie-Wen Peng; Gui-Nan Lin; Mei Li; Zhong-Jun Xia
Journal:  Med Oncol       Date:  2011-05-10       Impact factor: 3.064

5.  An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening.

Authors:  Christopher Leung; Edward Tsoi; Gareth Burns; William Sievert
Journal:  Oncologist       Date:  2011-04-04

6.  Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?

Authors:  Jinoos Yazdany; Leonard Calabrese
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

Review 7.  Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis.

Authors:  Pilar López-Serrano; Jose Lázaro Pérez-Calle; Maria Dolores Sánchez-Tembleque
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

Review 8.  Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.

Authors:  Evangelista Sagnelli; Mariantonietta Pisaturo; Salvatore Martini; Pietro Filippini; Caterina Sagnelli; Nicola Coppola
Journal:  World J Hepatol       Date:  2014-06-27

9.  Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Authors:  Shigeru Kusumoto; Luca Arcaini; Xiaonan Hong; Jie Jin; Won Seog Kim; Yok Lam Kwong; Marion G Peters; Yasuhito Tanaka; Andrew D Zelenetz; Hiroshi Kuriki; Günter Fingerle-Rowson; Tina Nielsen; Eisuke Ueda; Hanna Piper-Lepoutre; Gila Sellam; Kensei Tobinai
Journal:  Blood       Date:  2018-10-19       Impact factor: 22.113

Review 10.  Liver immunology.

Authors:  Dimitrios P Bogdanos; Bin Gao; M Eric Gershwin
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.